Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Advances and Updates in Migraine
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances and Updates in Migraine

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".

Deadline for manuscript submissions: 20 February 2026 | Viewed by 677

Special Issue Editors

Prof. Dr. Hartmut Göbel

E-Mail Website
Guest Editor
Kiel Migraine and Headache Center, 24149 Kiel, Germany
Interests: migraine; headache; neurology; pain management; diagnosis; comorbidity
Special Issues, Collections and Topics in MDPI journals
Dr. Carl H. Göbel

E-Mail Website
Guest Editor
1. Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, 24149 Kiel, Germany
2. Kiel Migraine and Headache Center, 24149 Kiel, Germany
Interests: migraine; headache; neurology

Special Issue Information

Dear Colleagues,

Migraine is the most prominent headache disorder and ranks third among all diseases worldwide, affecting nearly 15% of the global population annually. It is most prevalent in women aged 30 to 40 and is more common than diabetes, asthma, and epilepsy combined. Chronic migraine alone impacts approximately 2% of the world’s population. The WHO lists migraine as the leading cause of disability under the age of 50, especially in women. Headache disorders account for over 75% of all years lived with disability due to neurological diseases—surpassing stroke, dementia, Parkinson’s disease, multiple sclerosis, and epilepsy. Despite this immense burden, headache disorders are still underdiagnosed and undertreated. Comorbidities such as depression, anxiety, cardiovascular disease, and stroke—especially in young women—underline the urgent need for improved care structures.

This Special Issue aims to highlight cutting-edge advances in migraine research, diagnosis, and treatment. We welcome contributions addressing novel pathophysiological insights, genetic risk factors, precision medicine approaches, and innovations in acute and preventive therapies, including CGRP-antibodies, gepants, ditans, and neuromodulation. By bringing together clinical and translational research, this Special Issue seeks to catalyze change and mobilize the scientific community to reduce the individual and societal burden of migraine and headache disorders.

Prof. Dr. Hartmut Göbel
Dr. Carl H. Göbel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • migraine
  • chronic migraine
  • headache disorders
  • CGRP antibodies
  • gepants
  • ditans
  • triptans
  • precision medicine
  • neuromodulation
  • comorbidities
  • disability burden
  • pediatric migraine
  • ICHD-3 classification
  • neurotransmitters
  • preventive therapy
  • translational headache research

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 1737 KB  
Article
miR-197, miR-101, and miR-143 and Pro-Inflammatory Cytokines in Migraine
by Roberto Carlos Rosales-Gómez, Beatriz Teresita Martín-Márquez, Alvaro Jovanny Tovar-Cuevas, Omar Cárdenas-Saenz, Patricia Orozco-Puga, Milton Omar Guzmán-Ornelas, Nathan Alejandro Peña-Dueñas, Flavio Sandoval-García, Daniela Ortiz-Ríos, Mariana Chávez-Tostado, Diana Mercedes Hernández-Corona, Miriam Méndez-del Villar and Fernanda-Isadora Corona-Meraz
J. Clin. Med. 2025, 14(18), 6410; https://doi.org/10.3390/jcm14186410 - 11 Sep 2025
Viewed by 547
Abstract
Background: Migraine is a disabling neurological disorder where the release of neuropeptides and a local and systemic proinflammatory state prevail. MicroRNAs (miRs) are epigenetic regulators that control the expression of genes involved in inflammation, neovascularization, and pain-related processes. Cytokines mediate the inflammatory [...] Read more.
Background: Migraine is a disabling neurological disorder where the release of neuropeptides and a local and systemic proinflammatory state prevail. MicroRNAs (miRs) are epigenetic regulators that control the expression of genes involved in inflammation, neovascularization, and pain-related processes. Cytokines mediate the inflammatory state, while miRs can modulate their expression. Methods: This is an analytical and observational study in which subjects with a diagnosis of chronic and episodic migraine and healthy controls were recruited, and the migraine patients were classified by episodic or chronic migraine, as well as with or without aura. Cytokines were measured using the ELISA technique, and the microRNAs hsa-miR-197-3p, hsa-miR-101-3p, and hsa-miR-143-3p were evaluated using qPCR methodology. We also utilized bioinformatic tools, such as miRBase, TargetScan, miRNet, and miRPath, to analyze the interactions and pathways involved. Results: Our findings revealed that hsa-miR-197-3p is elevated in patients without aura (29.91 ± 11.14 with aura vs. 81.10 ± 53.85 without aura, RU; p = 0.021), whereas hsa-miR-143-3p is elevated in episodic migraine (0.0639 ± 0.0227 in EM vs. 0.0308 ± 0.0174, RU p = 0.011). Furthermore, we found higher levels of IL-17 (9.46 ± 1.06 in CM vs. 7.61 ± 2.12 in EM, p = 0.030), IL-6 (4.95 ± 2.84 in CM vs. 1.52 ± 0.98 non-migraine subjects, p = 0.016), and TNFα in chronic migraine patients (0.46 ± 0.24 in CM vs. 0.20 ± 0.05 in non-migraine, p = 0.011 and vs. 0.20 ± 0.13 in EM, p = 0.016). Conclusions: Inflammation is present in migraine regardless of the clinical characteristics of the patients, although it may be accentuated in chronic migraine. Our preliminary findings suggest a potential role for peripheral inflammatory markers, including specific microRNAs (miR-197, miR-101, and miR-143) and cytokines (TNF-α, IL-6, and IL-17A), in the pathophysiology of migraine. These results, although limited by sample size and cross-sectional design, highlight molecular pathways that warrant further investigation. Full article
(This article belongs to the Special Issue Advances and Updates in Migraine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop